These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, Bilder R. J Clin Psychiatry; 1996; 57 Suppl 9():5-9. PubMed ID: 8823344 [Abstract] [Full Text] [Related]
23. Understanding adherence to neuroleptic treatment in schizophreniaí. Vauth R, Löschmann C, Rüsch N, Corrigan PW. Psychiatry Res; 2004 Apr 15; 126(1):43-9. PubMed ID: 15081626 [Abstract] [Full Text] [Related]
24. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Glazer WM, Ereshefsky L. J Clin Psychiatry; 1996 Aug 15; 57(8):337-45. PubMed ID: 8752015 [Abstract] [Full Text] [Related]
25. Management strategies for the treatment of schizophrenia. Kane JM. J Clin Psychiatry; 1999 Aug 15; 60 Suppl 12():13-7. PubMed ID: 10372604 [Abstract] [Full Text] [Related]
27. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups. Curran S, Turner D, Musa S, Wattis J. Int J Geriatr Psychiatry; 2005 Sep 15; 20(9):842-7. PubMed ID: 16116576 [Abstract] [Full Text] [Related]
28. Prediction of course and therapeutic response in psychiatric diseases. Helmchen H. Pharmacopsychiatria; 1983 Nov 15; 16(6):173-4. PubMed ID: 6665026 [No Abstract] [Full Text] [Related]
31. Course of psychiatric disorders in pregnancy. Dilemmas in pharmacologic management. Altshuler LL, Szuba MP. Neurol Clin; 1994 Aug 15; 12(3):613-35. PubMed ID: 7990794 [Abstract] [Full Text] [Related]
32. Partial compliance in schizophrenia and the impact on patient outcomes. Llorca PM. Psychiatry Res; 2008 Nov 30; 161(2):235-47. PubMed ID: 18849080 [Abstract] [Full Text] [Related]
33. [Clinico-pharmacokinetic aspects of the optimization of psychopharmacotherapy]. Gor'kov VA, Panteleeva GP, Minsker EI. Zh Nevropatol Psikhiatr Im S S Korsakova; 1986 Nov 30; 86(4):567-73. PubMed ID: 3716709 [Abstract] [Full Text] [Related]
34. Contemporary psychopharmacotherapy in the context of brave new psychiatry, well-being therapy and life coaching. Jakovljević M. Psychiatr Danub; 2007 Sep 30; 19(3):195-201. PubMed ID: 17914319 [Abstract] [Full Text] [Related]
36. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Kinon BJ, Kane JM, Chakos M, Munne R. Psychopharmacol Bull; 1993 Sep 30; 29(3):365-9. PubMed ID: 7907184 [Abstract] [Full Text] [Related]
37. [Diagnostic principles for differential therapy of psychoses]. Hell D, Bridler R. Praxis (Bern 1994); 2001 May 31; 90(22):975-80. PubMed ID: 11450185 [Abstract] [Full Text] [Related]
38. Planning psychiatric treatment and rehabilitation for the long-term patient. Nguyen SD, Cebulski L. Psychiatr J Univ Ott; 1987 Mar 31; 12(1):9-15. PubMed ID: 3108917 [No Abstract] [Full Text] [Related]
40. An analysis of drug decisions in a state psychiatric hospital. Gillis JS, Moran TJ. J Clin Psychol; 1981 Jan 31; 37(1):32-42. PubMed ID: 6110676 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]